Tirzepatide
Mounjaro · Zepbound
Semaglutide's bigger, stronger cousin. Dual-action weight loss that's breaking clinical records.
What is Tirzepatide?
If Semaglutide was the revolution, Tirzepatide is the evolution. Made by Eli Lilly (vs Novo Nordisk's Semaglutide), it targets TWO receptors instead of one: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual action appears to produce even greater weight loss than Semaglutide alone.
The SURMOUNT trial results were staggering: patients lost an average of 22.5% of their body weight on the highest dose. That's nearly a quarter of total body weight — results that were previously only achievable with bariatric surgery.
How Does It Work?
Tirzepatide is a dual GIP/GLP-1 receptor agonist. GLP-1 suppresses appetite and slows gastric emptying (same as Semaglutide). GIP adds additional insulin secretion stimulation, improved fat metabolism, and may have direct effects on adipose tissue.
The dual action creates a synergistic effect — the two hormones working together produce greater metabolic improvements than either alone.
What Does The Research Say?
Strong clinical evidence from human trials.
SURMOUNT-1: 22.5% body weight loss at highest dose (15mg) over 72 weeks. SURMOUNT-2 (diabetes patients): 14.7% weight loss. SURMOUNT-3 (with lifestyle intervention): 26.6% weight loss. These are the highest weight loss numbers ever seen in a pharmaceutical trial.
Also approved for Type 2 diabetes (Mounjaro). Cardiovascular outcome trials are ongoing.
Reported Dosages
These are dosages reported in research literature and community reports. They are NOT medical recommendations. Always consult a healthcare professional.
Prescription only. Must be prescribed and supervised by a doctor.
Mounjaro/Zepbound: 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg weekly injection, escalated over 20 weeks.
Do NOT use without medical supervision.
Side Effects & Risks
Similar to Semaglutide: nausea, vomiting, diarrhea, constipation (especially during dose escalation). Potential for pancreatitis, gallbladder issues. Thyroid tumour risk (rodent studies). Muscle loss is a concern — strength training strongly recommended.
Legal Status by Country
Prescription only. Mounjaro approved for diabetes. Zepbound for weight management (pending).
Prescription only. FDA-approved (Mounjaro for diabetes, Zepbound for weight loss).
Prescription only. EMA-approved for diabetes.
Prescription only. TGA-approved for diabetes.
Important Disclaimer
This profile is for educational and research purposes only. It does not constitute medical advice. Tirzepatide may be regulated or illegal in your jurisdiction. Do not use any compound without consulting a qualified healthcare professional. StackPedia does not sell, supply, or promote the use of any controlled substance.